Stockscreener 앱 받기
7.63
5.24%
0.38
시간 외 거래:
7.63
전일 마감가:
$7.25
열려 있는:
$7.52
하루 거래량:
666.43K
Relative Volume:
0.94
시가총액:
$415.22M
수익:
$3.32M
순이익/손실:
$-156.76M
주가수익비율:
-2.6293
EPS:
-2.9019
순현금흐름:
$-140.13M
1주 성능:
-7.63%
1개월 성능:
-18.83%
6개월 성능:
-71.71%
1년 성능:
-29.61%
1일 변동 폭
$7.40
$7.86
1주일 범위
$7.185
$8.64
52주 변동 폭
$7.185
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
명칭
Upstream Bio Inc
전화
781-208-2466
주소
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
7.63 | 394.54M | 3.32M | -156.76M | -140.13M | -2.9019 |
VRTX
Vertex Pharmaceuticals Inc
|
428.34 | 107.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
618.95 | 63.21B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.14 | 49.89B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.58 | 38.20B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.99 | 32.17B | 742.00K | -1.37B | -1.07B | -7.0731 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-11-18 | 개시 | Evercore ISI | Outperform |
| 2025-10-14 | 개시 | Truist | Buy |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | Piper Sandler | Overweight |
| 2024-11-05 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 개시 | William Blair | Outperform |
모두보기
Upstream Bio Inc 주식(UPB)의 최신 뉴스
Upstream Bio schedules fireside chat at global healthcare event - Traders Union
H.C. Wainwright Initiates UpStream Bio(UPB.US) With Buy Rating, Announces Target Price $36 - Moomoo
UPB Initiates Coverage On HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
H.C. Wainwright initiates Upstream Bio stock coverage with buy rating By Investing.com - Investing.com Canada
Upstream Bio: The Reset Is The Opportunity, Initiating At Buy (NASDAQ:UPB) - Seeking Alpha
UPB Price Today: Upstream Bio, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Upstream Bio (UPB) price target decreased by 10.31% to 44.37 - MSN
UPB News | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Upstream Bio (UPB) Edges Higher Amid Quiet Trading, Holds Above Key SupportSupply Zone - thelegaladvocate.com
Upstream Bio Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEarnings Surprise Score - thelegaladvocate.com
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrowed Loss Per Share as Clinical Pipeline AdvancesEPS Growth Rate - thelegaladvocate.com
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower Than Expected Loss Reflects Operational DisciplineAI Trading Community - Newser
Upstream Bio (UPB) Q1 2026 Earnings: Narrower-Than-Expected Loss Amid No Revenue; Stock Edges LowerForward EPS Estimate - Newser
UPB Stock Price, Quote & Chart | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Number of shareholders of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
Upstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target - TipRanks
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference - Sahm
Upstream Bio (UPB) Reveals Promising Phase 2 Trial Results for V - GuruFocus
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data for verekitug in CRSwNP at ATS2026 - Traders Union
Upstream Bio Announces Positive Phase 2 VIBRANT Trial Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma - Quiver Quantitative
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial - GlobeNewswire
Upstream Bio, Inc. (UPB) reports Q1 loss, beats revenue estimates - MSN
Upstream Bio (UPB) Surges +3.41%, Nearing $9.54 Resistance 2026-05-17Market Analysis - newser.com
MSN Money - MSN
Truist Financial Reaffirms Their Buy Rating on Upstream Bio, Inc. (UPB) - The Globe and Mail
Upstream Bio lead drug pivotal trial plan follows strong phase 2 data - MSN
UPB Maintains Rating by Mizuho -- Price Target Lowered to $50.00 - GuruFocus
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM) and Upstream Bio, Inc. (UPB) - The Globe and Mail
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $42 to $43 - Moomoo
Mizuho lowers Upstream Bio stock price target on operating spend tweaks - Investing.com Canada
Mizuho Adjusts Price Target on Upstream Bio to $50 From $51, Maintains Outperform Rating - Moomoo
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - Sahm
Upstream Bio, Inc. 2026 Q1 Financials and Risk Factors – Nasdaq Global Select Market Filing - Minichart
Upstream Bio : Corporate Presentation May 2026 (May 13, 2026) - marketscreener.com
UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for major respiratory diseases - TradingView
Upstream Bio Reports Q1 2026 Results and Advances Verekitug Toward Phase 3 Trials for Severe Asthma, CRSwNP, and COPD - Minichart
UPB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Upstream Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Upstream Bio, Inc. 1Q 2026: Revenue $1.03M, EPS $(0.75) — 10-Q Summary - TradingView
Upstream Bio reports Q1 2026 net loss $40.6M; cash and short-term investments $294.6M - TradingView
Upstream Bio, Inc. (UPB) Eps Diluted (TTM) - Zacks Investment Research
TradingKey - TradingKey
Upstream Bio, Inc. $UPB Shares Bought by UBS Group AG - MarketBeat
Jennison Associates LLC Makes New Investment in Upstream Bio, Inc. $UPB - MarketBeat
773,148 Shares in Upstream Bio, Inc. $UPB Acquired by Pictet Asset Management Holding SA - MarketBeat
Upstream Bio Inc expected to post a loss of 77 cents a shareEarnings Preview - TradingView
Should I buy Upstream Bio, Inc. (UPB) - Zacks Investment Research
Upstream Bio down despite mid-stage trial win for asthma drug - MSN
Upstream Bio Inc (UPB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.59%
0.77%
자본화:
|
볼륨(24시간):